The Experiment Study and Mechanism of Aspirin Enhances Cellular Sensitivity of Hepatocellular Carcinoma Cell Line to Arsenic Trioxide

HU Ya-nan, GU Shi-yan, ZHANG Zun-zhen

Abstract

To explore whether aspirin could sensitize arsenic trioxide on human hepatocelluar carcinoma cell line and understanding the combination mechanisms underlying co-treatment. Methods Cell viability was detected by MTT assay, cell apoptosis rate and reactive oxygen species (ROS) level were measured by flow cytometry, and Western blot assay was used to estimated the protein expression of heme oxygenase-1 (HO-1) in total protein and NF-E2-related factor 2 (Nrf2) in nuclear protein. Results 10 μmol/L arsenic trioxide can decreased the cell viability, while cell apoptosis rate, ROS level, HO-1 and Nrf2 protein expression was increased ( P<0.05). When compared with arsenic trioxide alone, co-treatment of arsenic trioxide with aspirin in different concentration (0, 0.1, 1.0, 2.5, 5.0 mmol/L) exhibited dual effects in intracellular ROS level, HO-1 and Nrf2 expression. Specifically, with the increasing of aspirin concentrations, the level of ROS induced by arsenic trioxide showed a rising trend after the first reduction, whereas, HO-1 and Nrf2 protein expression were decreased at first and then increased. Conclusion Low concentration, less than 2.5 mmol/L, of aspirin may reduce the ROS accumulation through activating of Nrf2-HO-1 pathway, therefore decreasing the apoptotic cell death induced by arsenic trioxide. On the contrary, 5 mmol/L aspirin could increase the sensitivity of HepG2 to arsenic trioxide through enhancing the arsenic trioxide-induced apoptosis by ROS accumulation resulting in inhibiting the Nrf2-HO-1 pathway.

 

Keywords: Arsenic trioxide, Aspirin, Apoptosis HO-1 Nrf2 

 

Full Text:

PDF


References


Song X, Hu X. Lii S, et al. Incorporation of arsenic trioxide in induction therapy improves survival of patient with newly diagnosed acute promyelocytic leukaemia. Eur J Haematol, 2014;93(1):54-62.

Rothwell PM, Fowkes FG, Belch JF. et al. Effect of daily aspirin on long-term risk of death due to cancer; analysis of individual patient data from randomised trials. Lancet, 2011; 377(9759):31-41.

Goel A, Chang I)K. Ricciardiello L. et al. A novel mechanism for aspirin- mediated growth inhibition of human colon cancer cells. Clin Cancer Res,2003;9( 1);383-390.

Hossain MA, Kim DH, Jang JY. et al. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocelluar carcinoma cells in vitro and in vivo. Int J ncol,2012;40(5): 1636-1642.

Chen RH, Tian YJ. Enhanced anti-tumor efficacy of aspirin combined with triptolide in cervical cancer cells. Asian Рас J Cancer Prev,2013; 14(5) :3041-3044.

Li G. Zhang S. Fang H, et al. Aspirin overcomes Navitoclax- resistance in hepatocellular carcinoma cells through suppression of Mcl-1. Biochem Biophys Res Commun. 2013; 434 ( 4 ): 809- 814.

Pennarun B, Klleibeuker JH. Boersma-van Ek W, et al. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. J Pathol, 2013;229(3):410-421.

Alarifi S, Ali D. Alkahtani S, et al. Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther, 2013; 6 ; 75-84. doi;10. 2147/OTT. S38227.

Burdon RH. Control of cell proliferation by reactive oxygen species. Biochem Soc Trans, 1996; 24(4); 1028-1032.

Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Nat Cancer Inst .2007;99(8):608-615.

Ansari N. Khodagholi F. Amini M. 2-Ethoxy-4, 5-diphenyl-1, 3-oxazine-6-one activity the Nrf2/HO-l axis and protects against oxidative stress-induced neuronal death. Eur J Pharmacol, 2011; 658(2-3) s 84-90.

Kansanen E, Kuosmanen SM. Leinonen H, et al. The Keapl- Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol,2013; 1( 1):45-49.

Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest, 2006 ; 116 ( 4 ): 984- 995.


Refbacks

  • There are currently no refbacks.